{"id":"NCT01316276","sponsor":"Insmed Incorporated","briefTitle":"Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection","officialTitle":"Long Term Safety and Tolerability Study of Open-Label Liposomal Amikacin for Inhalation (ARIKACEâ„¢) in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10-05","primaryCompletion":"2015-07-16","completion":"2015-07-16","firstPosted":"2011-03-16","resultsPosted":"2019-07-26","lastUpdate":"2020-06-17"},"enrollment":206,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"Liposomal amikacin for inhalation","otherNames":[]}],"arms":[{"label":"LAI","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long term safety and tolerability of Liposomal Amikacin for Inhalation (LAI) 590 mg once daily (QD) in Cystic Fibrosis patients with chronic infection due to pseudomonas aeruginosa. This long-term, open-label, multi-cycle extension study enrolled subjects who had successfully completed study TR02-108, were compliant with the study protocol, and did not meet any of the listed study discontinuation criteria. The safety and tolerability of LAI were evaluated for up to approximately 2 years.","primaryOutcome":{"measure":"Treatment Emergent Adverse Events (TEAEs) up to Day 672","timeFrame":"From Study Initiation up to Day 672","effectByArm":[{"arm":"LAI 590 mg QD","deltaMin":183,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":50,"countries":["Austria","Belgium","Bulgaria","Canada","Denmark","France","Germany","Greece","Hungary","Ireland","Italy","Netherlands","Poland","Serbia","Slovakia","Spain","United Kingdom"]},"refs":{"pmids":["34144923"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":92,"n":206},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","Nasopharyngitis","Upper respiratory tract infection","Haemoptysis","Cough"]}}